BioCentury
ARTICLE | Company News

Biovail, Prestwick deal

September 22, 2008 7:00 AM UTC

Biovail bought Prestwick for $100 million in cash. The deal gives Biovail Canadian rights to Nitoman tetrabenazine to treat hyperkinetic movement disorders. Prestwick had U.S. and Canadian rights to ...